OQP Bio "Ovarian Cancer Treatment US FDA Global Phase 3 Clinical Trial 'Clinical Trials Started at National Cancer Center and 3 Other Hospitals'"

[Asia Economy Reporter Hyunseok Yoo] OQP Bio announced on the 15th that the global Phase 3 clinical trial of the ovarian cancer treatment ‘Oregobomab’ with the US FDA is progressing smoothly, and patient recruitment has begun at four major hospitals in Korea.

The global Phase 3 clinical trial has opened 96 clinical sites so far, and additional sites are being opened sequentially, accelerating the progress of the trial.

In Korea, patient recruitment for the clinical trial has started at the National Cancer Center, Seoul National University Bundang Hospital, Yonsei University Severance Hospital, and The Catholic University of Korea Seoul St. Mary’s Hospital. Clinical trials are also planned at Asan Medical Center and Korea University Hospital, where patient recruitment is currently being prepared.

An OQP official stated, “The domestic clinical trial is being conducted as part of the global clinical trial, and OQP Bio successfully obtained approval from the Ministry of Food and Drug Safety in May for the domestic clinical trial of the global Phase 3 trial,” adding, “Despite COVID-19, the Phase 3 trial is progressing smoothly, and patient recruitment is expected to begin this year at six major hospitals in Korea.”

OQP Bio is a corporation established following the spin-off of OQP’s bio division and is conducting global clinical trials for ovarian cancer treatment. In July this year, OQP held an extraordinary general meeting of shareholders and spun off OQP Bio, the bio business division, and Duol Mulsan Holdings, the investment and manufacturing management division, as new entities. Duol Mulsan, the largest shareholder of Duol Mulsan Holdings, completed approval for new registration on the K-OTC market and has been traded on the K-OTC market since the 13th of this month.

This content was produced with the assistance of AI translation services.